Derrick Snowdy is probably as close to a celebrity as Canada’s private investigator community has. Starting in 2010, Snowdy burst into view as a prime mover in the political controversy colloquially known as “the busty hookers scandal.”
Snowdy proved to be a quick study at capturing an audience’s attention, ever ready to regale listeners with some of the inside stories from his investigations. So when Catalyst Capital founder Newton Glassman brought a stemwinder of a defamation litigation in 2017 against a host of hedge fund managers and journalists, it was not surprising to see Snowdy involved. (Foundation for Financial Journalism readers will recall our two 2018 investigations that looked into the quality of disclosures at Callidus Capital and Catalyst Capital, the two investment vehicles Glassman controlled. In July 2019 Catalyst amended the initial defamation claim to add Bruce Livesey, the article’s co-author, as a defendant.)
After all, given the numerous well-heeled defendants — and their lawyers, many sporting big litigation budgets — the prospects for an investigator with a knack for digging into corporate fraud seemed attractive.
To U.S. oncologists who treat individuals with small cell lung cancer, lurbinectedin’s arrival was a big deal. The Food and Drug Administration permitted its sale in the United States under its accelerated approval program. Then the drug failed to meet the primary endpoint of its clinical trial’s Phase III.
Investors might be shocked to learn what lies behind the recent muscular share price growth of Freedom Holding Corp., a Las Vegas–incorporated bank and securities brokerage with its principal office in Almaty, Kazakhstan. Freedom Holding’s astronomical revenue growth has seemingly made it the fastest-growing financial services company on Earth.
Voluntary reports submitted to a Food and Drug Administration database, including entries from surgeons, paint a picture of a new Penumbra catheters whose safety problems the company may be forced to address in a substantive manner.
The U5 is one of the most important documents on Wall Street. And negotiations to discuss them can easily become a battleground where employers and employees fight over whether an upcoming exit will be classified as a resignation or a firing — and if problematic behavior is revealed.
For more than a decade Amy Walker, a research analyst in London, has been waging a ceaseless battle for justice in connection with what she alleges was a sexual assault by her colleague at Credit Suisse.
After five years of Fundamental Global Investors’ oversight, three public companies have weakened financially and their share prices have collapsed. Many minority investors in these three public companies, as well as the hedge fund’s limited partners, have absorbed steep losses.
Until late last year Dr. Quan Tran, a St. Petersburg, Florida, surgeon had an unusual side hustle. He served as one of three general partners of Q3 I LP, a cryptocurrency hedge fund that he helped launch in August 2017.
A high-profile research analyst who identifies and bets on troubled companies has acquired an unusual and perhaps unwarranted amount of influence in the brief period of time he’s been in this line of work.